Table 3. Expression of SIgA, IgG, IL-2 and IL-10 and IL-2/IL-10 ratio before treatment in HPV16- and HPV18-positive patients in test groups and the control group.
| Group | Number | SIgA | IgG | IL-2* | IL-10* | IL-2/IL-10 |
|---|---|---|---|---|---|---|
| Control | 9 | 1.624 (0.447) | 2.68 (1.28) | 55.66 (17.01) | 36.36 (21.42) | 3.09 (4.19) |
| LSIL | 56 | 1.06 (1.36) | 2.43 (3.17) | 62.5 (25.44) | 13.45 (6.59) | 9.78 (15.01) |
| HSIL | 112 | 1.34 (1.23) | 6.70 (8.24) | 42.50 (18.90) | 19.37 (8.86) | 3.99 (6.13) |
| CSCC | 28 | 1.52 (1.052) | 6.85 (10.13) | 83.65 (77.06) | 47.59 (15.85) | 2.27 (2.47) |
| P | 0.282 | 0.00035 | <0.0001 | <0.0001 | 0.00259 |
*, the difference between two groups is statistically significant.